The pharmaceutical company Inflazome (Roche) has developed two oral NLRP3 inhibitors, Inzomelid (NCT04086602) and Somalix, both of which have completed Phase 1 trials and have been tested in people with Cryopyrin-associated periodic syndrome (CAPS) (Coll et al., 2019). This evidence concerns the gene NLRP3 and cryopyrin-associated periodic syndrome.